Walmart shareholders face hurdle in new opioid fraud class action
8 Min Read (Reuters) - Two plaintiffs' firms filed a shareholder class action against Walmart on Wednesday in federal court in Wilmington, accusing the company of misleading investors about its opioid prescription practices in filings with the Securities and Exchange Commission between 2016 and 2020. The complaint, filed by the Rosen Law Firm and Farnan, alleged Walmart failed to inform shareholders that its pharmacies filled thousands of suspicious opioids prescriptions under a company policy that, according to the suit, kept pharmacists under pressure to fulfill orders instead of asking q...